AL
$6.70
+0.36
(+5.68%)
As of Oct 20, 2026, 5:13 PM EDT · cached
Price history
Alumis Inc (ALMS) is trading up at $6.70 (+5.68%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
IPO: June 28, 2024 · $16.00 offering · NASDAQ · View IPO details →
Alumis Inc revenue & net income history (FY2023–FY2025)
RevenueNet incomeNet margin (right axis, %)
| FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|
| Income statement | |||
| Revenue | — | — | $24.1M |
| Operating income | −$158.2M | −$300.8M | −$453.8M |
| Operating margin | — | — | −1886.9% |
| Net income | −$155.0M | −$294.2M | −$243.3M |
| Net margin | — | — | −1011.7% |
| EPS (diluted) | −$72.08 | −$10.38 | −$2.86 |
| Balance sheet | |||
| Cash and equivalents | $46.0M | $169.5M | $89.7M |
| Total assets | $89.6M | $341.0M | $411.9M |
| Total liabilities | $53.5M | $80.9M | $110.6M |
| Shareholders' equity | −$339.3M | $260.1M | $301.3M |
| Cash flow | |||
| Operating cash flow | −$130.0M | −$255.1M | −$369.5M |
| Capital expenditure | $4.50M | $1.73M | $653.0K |
| Free cash flow | −$134.5M | −$256.8M | −$370.2M |
| Share buybacks | $64.0K | $6.00K | $17.0K |
RevenueNet incomeNet margin (right axis, %)
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | $17.4M | $2.67M | $2.07M | — | $1.74M | $1.66M |
| Growth (year over year) | — | — | — | — | — | — | −90.0% | −37.7% |
| Operating income | −$98.4M | −$98.6M | −$101.5M | −$140.5M | −$115.3M | — | −$98.4M | −$148.9M |
| Operating margin | — | — | −583.9% | −5271.5% | −5580.4% | — | −5652.4% | −8956.4% |
| Net income | −$93.1M | −$94.8M | −$99.0M | $59.3M | −$110.8M | — | −$93.1M | −$142.2M |
| Net margin | — | — | −569.1% | 2225.1% | −5360.7% | — | −5344.8% | −8557.2% |
| EPS (diluted) | −$1.73 | $35.48 | −$1.82 | $0.77 | −$1.06 | — | −$0.74 | −$1.11 |
| Balance sheet | ||||||||
| Cash and equivalents | $213.4M | $169.5M | $128.5M | $151.8M | $65.3M | $89.7M | $63.9M | $63.7M |
| Total assets | $412.6M | $341.0M | $261.3M | $610.9M | $488.0M | $411.9M | $671.6M | $560.6M |
| Total liabilities | $64.2M | $80.9M | $93.0M | $125.6M | $103.2M | $110.6M | $104.6M | $108.5M |
| Shareholders' equity | $348.4M | $260.1M | $168.3M | $485.3M | $384.8M | $301.3M | $567.0M | $452.2M |
| Cash flow | ||||||||
| Operating cash flow | −$83.8M | −$74.8M | −$80.4M | −$106.4M | −$110.9M | — | −$87.1M | −$81.5M |
| Capital expenditure | $779.0K | $366.0K | $37.0K | $616.0K | $0 | — | $164.0K | $237.0K |
| Free cash flow | −$84.5M | −$75.1M | −$80.4M | −$107.0M | −$110.9M | — | −$87.2M | −$81.7M |
| Share buybacks | — | $0 | — | — | $0 | — | — | — |
From Alumis Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Alumis Inc
- Headquarters
- South San Francisco, California From SEC filings, Oct 2026
Recent News (3)
-
Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures New Phase 3 Data Demonstrates Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures
-
-
Tesla, Apple, Nvidia, Medtronic, Alumis, Robinhood, Fervo, and More Stocks That Explain Today’s Market
Tesla, Apple, Nvidia, Medtronic, Alumis, Robinhood, Fervo, and More Stocks That Explain Today’s Market
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International